Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Cash from Financing Activities for 16 consecutive years, with -$681738.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 50.54% to -$681738.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.7 million through Dec 2025, down 3525.79% year-over-year, with the annual reading at -$6.7 million for FY2025, 3525.79% down from the prior year.
  • Cash from Financing Activities hit -$681738.0 in Q4 2025 for Cumberland Pharmaceuticals, down from -$386879.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $3.9 million in Q1 2022 to a low of -$5.5 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged -$979420.0 across 5 years, with a median of -$1.0 million in 2022.
  • Biggest YoY gain for Cash from Financing Activities was 401.86% in 2022; the steepest drop was 619.86% in 2022.
  • Year by year, Cash from Financing Activities stood at -$735300.0 in 2021, then tumbled by 278.19% to -$2.8 million in 2022, then soared by 46.52% to -$1.5 million in 2023, then rose by 7.31% to -$1.4 million in 2024, then skyrocketed by 50.54% to -$681738.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for CPIX at -$681738.0 in Q4 2025, -$386879.0 in Q3 2025, and -$150797.0 in Q2 2025.